Toxicological Profile for 1,2,3-Trichloropropane

August 2021

U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "…effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
August 2021	Final toxicological profile released
May 2019	Draft for public comment toxicological profile released
August 2011	Addendum to the toxicological profile released
September 1992	Draft for public comment toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Malcolm Williams, D.V.M., Ph.D.

ATSDR, Office of Innovation and Analytics, Toxicology Section, Atlanta, GA

Lisa Ingerman, Ph.D., DABT
Jenny S. Crisman, B.S.
Laura McIlroy, B.A.

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, National Center for Environmental Assessment.

PEER REVIEWERS

1. Ghulam Ahmad Shakeel Ansari, Ph.D., The University of Texas Medical Branch at Galveston, Galveston, Texas

2. Dale Hattis, Ph.D., Research Professor, George Perkins Marsh Institute, Clark University, Worcester, Massachusetts

3. Helmut Zarbl, Ph.D., Professor in the Rutgers School of Public Health, Department of Environmental & Occupational Health, Director of the National Institute of Environmental Health Sciences (NIEHS), Piscataway, New Jersey

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER ii
FOREWORD iii
VERSION HISTORY v
CONTRIBUTORS & REVIEWERS vi
CONTENTS vii
LIST OF FIGURES ix
LIST OF TABLES x

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH 1
1.1 OVERVIEW AND U.S. EXPOSURES 1
1.2 SUMMARY OF HEALTH EFFECTS 1
1.3 MINIMAL RISK LEVELS (MRLs) 5

CHAPTER 2. HEALTH EFFECTS 8
2.1 INTRODUCTION 8
2.2 DEATH 36
2.3 BODY WEIGHT 37
2.4 RESPIRATORY 37
2.5 CARDIOVASCULAR 38
2.6 GASTROINTESTINAL 38
2.7 HEMATOLOGICAL 39
2.8 MUSCULOSKELETAL 40
2.9 HEPATIC 40
2.10 RENAL 41
2.11 DERMAL 42
2.12 OCULAR 42
2.13 ENDOCRINE 43
2.14 IMMUNOLOGICAL 43
2.15 NEUROLOGICAL 44
2.16 REPRODUCTIVE 45
2.17 DEVELOPMENTAL 45
2.18 OTHER NONCANCER 47
2.19 CANCER 47
2.20 GENOTOXICITY 47

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS 50
3.1 TOXICOKINETICS 50
3.1.1 Absorption 50
3.1.2 Distribution 50
3.1.3 Metabolism 51
3.1.4 Excretion 54
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 54
3.1.6 Animal-to-Human Extrapolations 55
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 55
3.3 BIOMARKERS OF EXPOSURE AND EFFECT 56
3.3.1 Biomarkers of Exposure 57
3.3.2 Biomarkers of Effect 57
3.4 INTERACTIONS WITH OTHER CHEMICALS 58

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION 59
4.1 CHEMICAL IDENTITY 59
4.2 PHYSICAL AND CHEMICAL PROPERTIES 59

CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE 61
5.1 OVERVIEW 61
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 62
5.2.1 Production 62
5.2.2 Import/Export 62
5.2.3 Use 63
5.2.4 Disposal 63
5.3 RELEASES TO THE ENVIRONMENT 63
5.3.1 Air 64
5.3.2 Water 65
5.3.3 Soil 65
5.4 ENVIRONMENTAL FATE 66
5.4.1 Transport and Partitioning 66
5.4.2 Transformation and Degradation 67
5.5 LEVELS IN THE ENVIRONMENT 68
5.5.1 Air 69
5.5.2 Water 70
5.5.3 Sediment and Soil 70
5.5.4 Other Media 71
5.6 GENERAL POPULATION EXPOSURE 71
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 72

CHAPTER 6. ADEQUACY OF THE DATABASE 73
6.1 Information on Health Effects 73
6.2 Identification of Data Needs 73
6.3 Ongoing Studies 80

CHAPTER 7. REGULATIONS AND GUIDELINES 81

CHAPTER 8. REFERENCES 83

APPENDICES
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR 1,2,3-TRICHLOROPROPANE B-1
APPENDIX C. USER'S GUIDE C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS D-1
APPENDIX E. GLOSSARY E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS F-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to 1,2,3-Trichloropropane 2

1-2. Health Effects Found in Animals Following Oral Exposure to 1,2,3-Trichloropropane 3

1-3. Summary of Sensitive Targets of 1,2,3-Trichloropropane – Inhalation 5

1-4. Summary of Sensitive Targets of 1,2,3-Trichloropropane – Oral 6

2-1. Overview of the Number of Studies Examining 1,2,3-Trichloropropane Health Effects 11

2-2. Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 16

2-3. Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 29

3-1. Possible Metabolic Pathways for the Formation of ACPC, CPC, and GMA from 1,2,3-Trichloropropane 53

5-1. Number of NPL Sites with 1,2,3-Trichloropropane Contamination 61

6-1. Summary of Existing Health Effects Studies on 1,2,3-Trichloropropane By Route and Endpoint 74

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 1,2,3-Trichloropropane 7

2-1. Levels of Significant Exposure to 1,2,3-Trichloropropane – Inhalation 12

2-2. Levels of Significant Exposure to 1,2,3-Trichloropropane – Oral 20

2-3. Levels of Significant Exposure to 1,2,3-Trichloropropane – Dermal 34

2-4. Possible Associations Between Maternal Residential Proximity to 1,2,3-Trichloropropane Air Emissions and Birth Defects 46

2-5. Genotoxicity of 1,2,3-Trichloropropane *In Vitro* 48

2-6. Genotoxicity of 1,2,3-Trichloropropane *In Vivo* 49

4-1. Chemical Identity of 1,2,3-Trichloropropane 59

4-2. Physical and Chemical Properties of 1,2,3-Trichloropropane 60

5-1. Facilities that Produce, Process, or Use 1,2,3-Trichloropropane 62

5-2. Releases to the Environment from Facilities that Produce, Process, or Use 1,2,3-Trichloropropane 64

5-3. Lowest Limit of Detection Based on Standards 68

5-4. 1,2,3-Trichloropropane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites 69

7-1. Regulations and Guidelines Applicable to 1,2,3-Trichloropropane 81